Keros Therapeutics Inc News - KROS | ADVFN

Register to chat with like-minded investors on our interactive forums.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Keros Therapeutics Inc (KROS)
Keros Therapeutics Inc (KROS) News

Keros Therapeutics Inc (KROS)

11.84

0.45

(3.95%)

Closed January 24 4:00PM

Delayed by 15 minutes

11.51

-0.33

( -2.79% )

Pre Market: 7:33AM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a...

Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a...

Form 8-K - Current report

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Form 8-K - Current report

Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference

LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Form 8-K - Current report

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial

LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Form 8-K - Current report

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

1
2
Next

TheFinalCD

TheFinalCD 2 weeks ago

$KROS halts all dosing in the TROPOS Phase 2 clinical trial of cibotercept (KER-012) based on the ongoing safety review due to new observations of pericardial effusion adverse events

https://x.com/BioStocks/status/1879492237891080688

$KROS the TROPOS trial is being terminated early. The Co continues to expect to present topline data from all treatment arms in this trial in Q2
https://x.com/BioStocks/status/1879493199288586404

retireat40

retireat40 1 month ago

Wow. What a turd

retireat40

retireat40 1 month ago

Shocked this is still sub 18

Dennis14

Dennis14 2 months ago

Bought in at 18.00

Monksdream

Monksdream 4 months ago

KROS more upside possible

Monksdream

Monksdream 11 months ago

KROS new 52=week high

Keros Therapeutics

Delayed Upgrade Clock